Skip to main content
. 2016 Apr 26;7(21):30907–30923. doi: 10.18632/oncotarget.9023

Figure 1. Effects of acute treatment with the BRAF V600E inhibitor vemurafenib on two PTC cell lines.

Figure 1

(A) KTC1 and BCPAP cells were grown for 2 days in presence of 2.0 μM vemurafenib. KTC1 cells are shown to be more sensitive to the BRAF V600E inhibitor than BCPAP cells. (B, C) Western blot analysis of ERK1/2 and AKT activation in the same cell lines following 1, 4, and 24 hours exposure to 2.0 μM vemurafenib. A sharp reduction in phosphorylated ERK1/2 is maintained in KTC1 cells, but begins to recover in BCPAP cells after 4 hours of treatment. Phosphorylated AKT gradually drops over 24 hours in both lines, but to a lesser degree in the BCPAP line.